Utama › Kanser Ginjal (Karsinoma Sel Renal) › Nebraska › Omaha
Kajian klinikal Kanser Ginjal (Karsinoma Sel Renal) di Omaha, NE
12 kajian untuk Kanser Ginjal (Karsinoma Sel Renal) sedang mencari peserta di lokasi dalam dan sekitar Omaha (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
Mengambil pesertaFasa 1
- Research Site, Omaha
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
Mengambil pesertaFasa 1
- NEO-811 Omaha Site, Omaha
A Phase 1 Study of the Safety and Tolerability of CTX-10726
Mengambil pesertaFasa 1
- Nebraska Cancer Specialists, Omaha
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
- Alegent Health Immanuel Medical Center, Omaha
- Alegent Health Bergan Mercy Medical Center, Omaha
- Alegent Health Lakeside Hospital, Omaha
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Mengambil pesertaFasa 1
- Exelixis Clinical Site #2, Omaha
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Mengambil pesertaFasa 2
- Nebraska Medicine-Village Pointe, Omaha
- University of Nebraska Medical Center, Omaha
- Nebraska Medicine-Bellevue, Bellevue · 9 mi jauh
A Study of Theranostic Pair PD-32766D/T in Participants With Carbonic Anhydrase IX Positive Clear Cell Renal Cell Carcinoma
Mengambil pesertaFasa 1
- Research site, Omaha
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
Mengambil pesertaFasa 2
- Nebraska Medicine-Village Pointe, Omaha
- University of Nebraska Medical Center, Omaha
- Nebraska Medicine-Bellevue, Bellevue · 9 mi jauh
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Mengambil pesertaFasa 1
- The University of Nebraska Medical Center, Omaha
A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
Mengambil pesertaFasa 3
- Oncology Hematology West P.C. dba Nebraska Cancer Specialists ( Site 0131), Omaha
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Mengambil pesertaFasa 1/2
- Nebraska Cancer Specialists, Omaha
Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
Mengambil pesertaFasa 3
- Nebraska Cancer Specialists/Oncology Hematology West PC - MECC, Omaha
- Nebraska Methodist Hospital, Omaha
- Oncology Associates PC, Omaha
Kajian Kanser Ginjal (Karsinoma Sel Renal) di bandar lain
- Houston, TX35 kajian
- New York City, NY27 kajian
- Nashville, TN23 kajian
- Dallas, TX23 kajian
- St. Louis, MO23 kajian
- Los Angeles, CA20 kajian
- Boston, MA16 kajian
- Baldwin Park, CA16 kajian
- Philadelphia, PA15 kajian
- Pittsburgh, PA15 kajian
- Queens, NY15 kajian
- Rochester, MN14 kajian
Kajian lain di Omaha
- Kanser Prostat27 kajian
- Kanser Paru-paru Bukan Sel Kecil24 kajian
- Kanser Payudara22 kajian
- Kanser (semua jenis)18 kajian
- Kanser Kolorektal18 kajian
- Mieloma Pelbagai16 kajian
- Kanser Ovari14 kajian
- Limfoma Bukan Hodgkin14 kajian
- Kanser Pankreas14 kajian
- Kanser Metastatik13 kajian
- Karsinoma Sel Skuamosa Kepala dan Leher13 kajian
- Kegagalan Jantung13 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.